Stroke remains a leading cause of death and disability worldwide. An increasing number of animal studies and preclinical trials have, however, provided evidence that regenerative cell-based therapies can lead to functional recovery in stroke patients. Stem cells can differentiate into neural lineages to replace lost neurons. Moreover, they provide trophic support to tissue at risk in the penumbra surrounding the infarct area, enhance vasculogenesis, and help promote survival, migration, and differentiation of the endogenous precursor cells after stroke. Stem cells are highly migratory and seem to be attracted to areas of brain pathology such as ischemic regions. The pathotropism may follow the paradigm of stem cell homing to bone marrow and leukocytes migrating to inflammatory tissue. The molecular signaling therefore may involve various chemokines, cytokines, and integrins. Among these, stromal cell-derived factor-1 (SDF-1)/CXC chemokine receptor-4 (CXCR4) signaling is required for the interaction of stem cells and ischemia-damaged host tissues. SDF-1 is secreted primarily by bone marrow fibroblasts and is required for BMSC homing to bone marrow. Overexpression of SDF-1 in ischemic tissues has been found to enhance stem cell recruitment from peripheral blood and to induce neoangiogenesis. Furthermore, SDF-1 expression in the lesioned area peaked within 7 days postischemia, in concordance with the time window of G-CSF therapy for stroke. Recent data have shown that SDF-1 expression is directly proportional to reduced tissue oxygen tension. SDF-1 gene expression is regulated by hypoxic-inducible factor-1 (HIF-1), a hypoxia-dependent stabilization transcription factor. Thus, ischemic tissue may recruit circulating progenitors regulated by hypoxia through differential expression of HIF-1α and SDF-1. In addition to SDF-1, β2-integrins also play a role in the homing of hematopoietic progenitor cells to sites of ischemia and are critical for their neovascularization capacity. In our recent report, increased expression of β1-integrins apparently contributed to the local neovasculization of the ischemic brain as well as its functional recovery. Identification of the molecular pathways involved in stem cell homing into the ischemic areas could pave the way for the development of new treatment regimens, perhaps using small molecules, designed to enhance endogeneous mobilization of stem cells in various disease states, including chronic stroke and other neurodegenerative diseases. For maximal functional recovery, however, regenerative therapy may need to follow combinatorial approaches, which may include cell replacement, trophic support, protection from oxidative stress, and the neutralization of the growthinhibitory components for endogenous neuronal stem cells.
INTRODUCTION
replace infarcted central nervous system (CNS) tissue in an organotypically appropriate manner (36) . Moreover, cell-based approaches could provide trophic support to Ischemic stroke caused by cerebral artery occlusion leading to infarction of brain tissue remains a leading tissue at risk in the penumbra surrounding the infarct area, or help promote survival, migration, and differenti-cause of death and disability worldwide (119) . Although thrombolytic therapy poststroke shows significant clini-ation of the endogenous precursor cells after stroke (36) . It may seem unrealistic to induce functional recovery by cal benefits (43) , only a minority of patients have access to this therapy. Therefore, it is crucial that new alterna-replacing cells lost in stroke, considering the complexity of the human brain structure and function. However, tive therapeutic strategies are developed. The most encouraging approach has been directed toward employing studies in animal models have demonstrated that neuronal replacement and partial reconstruction of damaged stem cell-based therapies in ischemic stroke patients to neuronal circuitry is possible. There is also evidence, of multiple cell survival pathways, and 3) induction of adult stem cell differentiation (102). from clinical trials, that cell replacement in the diseased human brain can lead to symptomatic relief (71). REGENERATIVE THERAPY FOR STROKE Stem cells are immature cells with a prolonged self-IN ANIMAL MODELS renewal capacity and the ability to repopulate into multiple cell types. Different types of stem cells can be Several different types of stem cells, such as those from the umbilical cord blood (24, 120, 123) , fetal corti-distinguished based on their developmental origin into embryonic, fetal, and adult stem cells and others. Em-cal tissue (33, 78) , stem cell line (82) , fetal carcinoma cell line (17) , and neuronal progenitor cells (47, 50) have bryonic stem cells derived from the blastocyst are totipotent and give rise to progenies of the embryonic germ been successfully used to induce neurogenesis and functional recovery in various experimental models of cere-cell layers. Fetal stem cells represent more restricted progenitor cells harvested from fetal organs still under-bral ischemia. In the allogeneic setting, however, a major limitation to stem cell therapy has been the high going major developmental changes. The use of embryonic or fetal stem cells, however, raises serious biologi-incidence of acute and chronic graft-versus-host diseases and their potential negative impact on survival (30, 92) . cal, ethical, and legal questions in the clinic, limiting the widespread use of these cells at present (36) . Adult
An attractive option to improve functional recovery after ischemic brain lesion is the use of autologous autologous stem cells derived from the CNS [neural stem cells (NSCs)], bone marrow (BMSC) or peripheral BMSCs. Bone marrow contains precursors for HSCs and mesenchymal stem cells. Animal studies have dem-blood (PBSC) are very attractive alternative sources for cell-based therapies for the CNS. Adult stem cell ther-onstrated that injection of BMSCs in the infarct border zone results in regeneration of neurons with improved apy for stroke can be divided in endogenous and exogenous approaches. The aim of endogenous stem cell ther-survival rate and brain function after cerebral ischemia (23, 67) . BMSCs appear to have the ability to pass apy is to exploit, by mobilization from the bone marrow or stimulation with cytokines such as VEGF, the popula-through the blood-brain barrier and selectively migrate to the ischemic hemisphere of the damaged brain to im-tion of adult stem cells already physiologically present either in the CNS or hematopoietic system to replace prove neurological functions in experimental stroke animal models (23, 26, 109) . Furthermore, BMSCs are multi-lost neurons. In exogenous therapy, CNS or hematopoietic system-derived adult precursor cells are adminis-potent, and some transplanted BMSCs can differentiate into neurons and endothelial cells, which consequently tered, after purification and propagation in culture, locally or systemically following acute cerebral ischemia contribute to neovascularization in the damaged brain (23) . to yield functional improvement (36) .
Recent findings in rodents suggest another approach CLINICAL TRIALS OF REGENERATIVE to cell therapy in stroke is self-repair (71). Neurogenesis
THERAPY IN STROKE
in the adult brain is responsive to environmental changes, such as physical activity and stress (59) , or to In a previous clinical trial, patients with chronic stroke affecting the basal ganglia received implants of neuropathological processes such as stroke (15). Stroke leads to increased generation of neurons from NSCs in neurons generated from the human NT-2 teratocarcinoma cell line into the infracted area. Functional im-the subventricular zone (SVZ) (6, 91) . These immature neurons migrate into the damaged striatum, where they provements in some affected individuals correlated with increased metabolic activity at the grafted site (64, 80) . express markers of striatal neurons. Thus, the new neurons seem to differentiate into the phenotypes of the Our recent study also demonstrated significant longterm neurological improvement in patients treated sub-neurons destroyed by the ischemic lesion. However, because over 80% of the new neurons die during the first cutaneously within 7 days of ischemic stroke with granulocyte colony-stimulating factor (G-CSF), which is weeks after stroke, they only replace a small fraction (ϳ2%) of the mature striatal neurons that have died (6) . known to mobilize hemopoietic stem cells (HSCs) from the bone marrow to the peripheral blood. Furthermore, There is no substantial formation of new neurons in the cerebral cortex after stroke. However, the restricted self-higher 18 FDG uptake surrounding the ischemic core, which correlated with motor function improvement, was repair capacity in the ischemically damaged cortex is probably due to lack of cues necessary to trigger neuro-observed in the G-CSF group than in the control group (109) . The neuroplastic effects of G-CSF may include: genesis from the putative local parenchymal NSCs or migration of neuroblasts from the SVZ. Several factors 1) mobilization of stem cells from the bone marrow, and their subsequent homing to the ischemic brain (110) , 2) can increase adult neurogenesis by stimulating formation and/or improving survival of new neurons, includ-antiapoptotic activity in mature neurons and activation ing fibroblast growth factor 2 (FGF-2), epidermal growth tial role in enhancing endogenous neurogenesis and improves functional recovery in ischemic animal models factor (EGF), stem cell factor, erythropoietin, brainderived neurotrophic factor, caspase inhibitors, and anti- (2, 7, 8, 34, 98, 104) . Endothelial progenitor cells (EPCs) are mobilized from bone marrow during ischemia inflammatory drugs (25, 35, 51, 61, 101, 105) . These cytokines may act as survival, growth, and/or differentiation (106, 115) or exogenously by stimulation with cytokines such as VEGF and contribute to neovasculization of is-factors for neuronal and vascular progenitor cells, which may in turn proliferate, migrate, and differentiate fol-chemic tissues (7, 9, 115) or tumors (74) . Infusion of EPCs or isolated hematopoietic progenitor cells augmented lowing brain injury, thus contributing to the recovery processes (121).
neovascularization of ischemic myocardium and improved left ventricular function after myocardial ische-MECHANISMS UNDERLYING mia in both human and animal studies (12, 55, 58, 60) .
THE THERAPEUTIC EFFECTS
EPCs are preferentially recruited to sites of ischemia and OF STEM CELL THERAPY incorporated into vascular structures (1, 7, 8, 55, 115) . In our study of stroke rats treated with G-CSF or trans-Although the transplanted stem cells can survive and partly reverse behavioral deficits after ischemic stroke, planted PBSCs, we observed that mobilized stem cells labeled with BrdU contributed to reendothelialization the mechanisms underlying the observed improvement are unclear and there is little evidence for neuronal re-and angiogenesis in the perivascular area of the penumbric region of the brain (108, 110) . A recent study also placement. The degree of differentiation and integration of the transplanted cells often correlates poorly with the indicated that while peripheral stem cells themselves showed limited incorporation, they served to stimulate observed functional benefits (71,107). However, it has been recently recognized that donor tissues and cells of-angiogenesis and perhaps enhanced neurogenesis. Moreover, suppression of neovascularization by subcutaneous fer more than a source of immature progenitors potentially capable of cell replacement (88) . It is likely that injection of endostatin, an antiangiogenic agent, impaired neurogenesis after stroke (114) . Enhanced pro-the mechanisms providing therapeutic benefit to stroke rats using cell therapy are multidimensional.
duction of trophic factors, such as BDNF (65) and PDGF (53) by CD34 + cell-derived neovasculatures, may di-Interaction of stem cells with ischemic tissue may lead stem cells and/or parenchymal cells to produce tro-rectly result in differentiation of these CD34 + stem cells into neuron/glial cells (38) . Furthermore, CD34 + cell-phic factors that may contribute to the recovery of neural function lost as a result of tissue injury (87, 88) . BMSCs derived neovasculatures contributing to maintain newly formed neuron/glial cells have been shown to integrate have been shown to constitutively express interleukins, such as IL-1β, IL-8, IL-16, FGF-2, VEGF, IGF-1, GM-into networks in adult animals (72) , and to provide an environment conducive to neurogenesis (118). CSF, and TNF-α (76) . These neurotrophic factors have been shown to enhance neuronal sprouting, synaptogen-MOLECULAR SIGNALS esis, and neurotransmission, as well as increase neuro-IN STEM CELL HOMING transmitter release (27, 32, 56, 70) . A recent study also showed that the majority of functional neurons after Recent studies have revealed that stem cells are highly migratory and seem to be attracted to areas of brain pa-NSC transplantation were "rescued" host cells, which suggests that infarcted tissue may benefit not only from thology such as ischemic regions (1,23). While stem cell homing to bone marrow has been well studied (86), the NSC-derived replacement of lost neurons but also from the "chaperone" effects of some NSC-derived progeny molecular basis of stem cell pathotropism is not well understood. Further identification of the mechanisms in- (87) . Furthermore, there is evidence that neural stem cells can prevent the degeneration of striatal neurons volved would pave the way for the development of treatments to enhance endogenous mobilization of stem cells when transplanted into the CNS prior to toxin administration (75). Hanabusa et al. also demonstrated in vivo in disease states, perhaps using small molecules. Stem cells express a wide variety of receptors that may enable that BMSCs induced angiogenesis, neurogenesis, and inhibited cell apoptosis in the ischemic penumbra (37) . them to respond to many chemotactic signals that emanate from brain pathologies. Among these, the factors Thus, stem cells have neuroprotective effects not only directly, through their differentiation, but also through belonging to the chemokine superfamily seem to be very important (29, 46, 84, 122) . Chemokine and cytokine pro-their ability to induce trophic and antiapoptotic factors either by themselves or by interaction with host cells.
duction is a common feature of many brain lesions, including stroke, which suggests that these factors could Accumulating evidence suggests that vasculogenesis, mediated by circulating bone marrow-derived endothe-be important in mediating the responses of stem cells to pathology. In addition, stem cells interact with patho-lial progenitor or hemopoietic stem cells, plays an essen-gen-activated endothelial cells from the luminal side, ad-potential mechanism for mobilization of BMSCs in peripheral blood (28) . That circulating stem cells home to hering and transmigrating in a similar fashion to leukocytes (4, 97) . Recent studies have demonstrated that loci of high SDF-1 concentration is also supported by in vitro data (63) . Overexpression of SDF-1 in ischemic integrin-mediated adhesion and transmigration are involved in the homing of transplanted hematopoietic stem tissues has been found to enhance BMSC recruitment from peripheral blood and to induce neoangiogenesis cells to bone marrow (90) , as well as the recruitment of stem cells to sites of angiogenesis (117). Here we review (42, 125) . Lesion-induced upregulation of endothelial SDF-1 (112) and the appearance of increased CXCR4 several recent studies that have examined how chemokines and adhesion molecules contribute to stem cell pa-expression in the ischemic hemisphere in our previous study (110) indicate that cerebroendothelial SDF-1 could thotropism.
be a chemoattractant for peripheral blood cells. Further-Stromal Cell-Derived Factor-1 (SDF-1) and CXC more, the administration of CXCR4 antibody compro-Chemokine Receptor-4 (CXR- 4) mised BMSCs homing in the penumbric area of cerebral ischemic rats, resulting in poor neurological recovery SDF-1 (CXCL12) is a member of the alpha (CXC) chemokine family-small chemoattractant molecules after stroke (110) . These data demonstrated that SDF-1/ CXCR4 interactions represent the link between ischemic that are involved in inflammatory responses (77) . SDF-1 and its receptor CXCR4 have been demonstrated to tissue and BMSCs, which may be directly involved in vascular remodeling, angiogenesis, and neurogenesis, play an important role in the mobilization and homing of stem cells to bone marrow (3, 39, 40, 96) , endothelial thereby alleviating stroke symptoms. It has also recently been reported that several CXCR4-positive tumor cell cell migration, as well as in adult vasculogenesis (81, 99, 100, 125) , neurogenesis, and neuronal migration (69,73, types metastasize to bone tissue. Therefore, the SDF-1 secreted by bone marrow stromal cells may play a key 116). In vivo gene inactivation of SDF-1 and its receptor CXCR4 in mice leads to early embryonic lethality due role in metastasis of CXCR4-positive tumor cells to bone (68, 83) . to abnormal cerebellar, gastrointestinal vasculature, and hematopoetic development (86, 113, 126) .
Integrins SDF-1 is secreted primarily by bone marrow fibroblasts and is required for BMSC homing/retention in the Homing of stem cells to BM or ischemic tissue could follow the paradigm of mature leukocytes migrating to bone marrow microenvironment. A concentration gradient of SDF-1 across the endothelium in bone marrow is inflammatory tissue (79) . Multiple studies have shown that α4β1 ligand interactions can contribute to leuko-the major mechanism for homing of BMSCs to bone marrow (95). Physiologically, bone marrow has a higher cytes tethering/rolling, adhesion, and transendothelial migration during inflammation (5, 14, 16, 31, 45, 48, 49, 54) . SDF-1 concentration than any other tissue, and circulating BMSCs home to bone marrow proficiently. Because Pretreatment of anti-α4β1-integrin antibody decreases BM homing of transplanted murine hematopoietic stem mobilized peripheral blood stem cells are increasingly used for clinical cell transplantation, it is becoming clear cells (89). Our recent data showed that intracranial PBSC transplantation can significantly improve neuro-that proteolytic degradation of SDF-1 and CXCR4 in stem cells is an important step in stem cell release and logical function following chronic cerebral ischemia in rats, accompanied by increased local cortical cerebral homing (66, 96) . SDF-1 regulates adhesion/chemotaxis of bone marrow hematopoietic progenitor cells through blood flow and β1-integrin expression in the ischemic hemisphere (108) . The neurological improvement in this activation/regulation of specific integrin molecules (52, 94, 124) . Systemic administration of G-CSF activates study was blocked by the addition of synthetic RDG peptide (β1-integrin inhibitor) (108). These results sug-neutrophil elastases, then cleaves the membrane-bound SDF-1 of stromal cells in the bone marrow and provokes gest that β1-integrin is necessary for neuroplasticity after intracerebral stem cell transplantation, possibly via an efflux of CXCR4 (+) stem cells into circulation (96). Furthermore, plasma elevation of SDF-1 is involved in the enhanced angiogenesis via stem cells homing to ischemic lesions (108). BMSC mobilization through matrix metalloproteinase-9 (MMP-9)-mediated conversion of kit ligand factor Recent data have also shown that β2-integrins mediate the adhesion and transmigration of EPCs as well as (SCF) from membrane-bound to soluble form (41) .
A possible role for SDF-1 in the homing of stem cells hemopoietic stem/progenitor cells in vitro (21, 93, 94) . Moreover, β2-integrins are involved in the homing of to damaged sites has been unraveled by studies in animal models of liver, limb, heart, and brain damage (11, hematopoietic progenitor cells to sites of ischemia and are critical for their neovascularization capacity in vivo 19, 57, 62, 112, 125) . SDF-1 expression following hindlimb ischemia in mice was upregulated in plasma and (21) . Preactivation of β2-integrins on adult EPCs has been shown to significantly augment the in vivo neovas-downregulated in bone marrow, thus providing a novel cularization capacity of EPCs, whereas β2 −/− animals activated by oxygen-dependent stabilization of HIF-1α (19) . HIF-1 is a heterodimeric protein that is composed display a neovascularization defect in a model of hindlimb ischemia (21) . Whether β2and β1-integrins play of HIF-1α and HIF-1β subunits. HIF-1β is constitutively expressed, whereas HIF-1α expression is precisely regu-the same cellular role or whether different cell types use distinct mechanisms for homing remains to be deter-lated by the cellular oxygen concentration. HIF-1α accumulates instantaneously under hypoxic conditions and is mined. Further studies are still needed to elucidate whether there is a synergistic role between other adhe-rapidly degraded on reoxygenation. In normoxia, oxygen availability enables a specific prolyl hydroxylation, sion molecules and their counterligands in the multistep recruitment of adult endothelial progenitor and stem which allows HIF-1α binding to the von Hippel-Lindau protein, leading to ubiquitylation and degradation of cells to ischemic tissue (85) . Modulation of these integrins may provide novel opportunities for treating cere-HIF-1α. Three isoforms of the HIF prolyl hydroxylase domain protein (PHD), a family of iron and 2-oxoglutar-bral ischemic disease.
ate-dependent dioxygenases, have been identified. Oxy-THE TIME WINDOW FOR REGENERATIVE gen availability also enables asparaginyl hydroxylation THERAPY FOR STROKE of the transactivation domain of HIF-1α, blocking interaction with transcriptional coactivators, an event gov-We have recently demonstrated that administering G-CSF 7 days after focal cerebral ischemia did not result erned by an oxygen-dependent asparaginyl hydroxylase, termed factor-inhibiting HIF-1 (FIH-1). in stem cell engraftment into the infarct zone or improvement in brain function in rats despite a 25-fold in-Thus, under normoxic conditions, HIF-1α subunits are modified by prolyl and asparaginyl hydroxylation, crease in the number of circulating CD34 + cells (109) . Similarly, intravenous BMSCs increased stem cell hom-leading to their instability and functional inactivation. In hypoxia, however, the PHD and FIH are inactive, result-ing, angiogenesis, and improved cardiac function if administered within 1 day after myocardium infarction, ing in stable and active HIF-1α subunits. The HIF-1α/ HIF-1β dimers then activate hypoxia-response elements whereas no effects were found when infusion was initiated 7 or 14 days postischemia (10) . In concordance to in HIF-1-targeted genes to modulate specific gene transcription (20) . In the brain, HIF-1α expression seems to the above findings, cerebral SDF-1 expression decreased progressively 7-14 days postischemia (112) . Our re-be induced by hypoxia in neurons, astrocytes, ependymal cells, and endothelial cells. HIF-1 is induced promptly cently developed chronic stroke model indicates that intracerebral transplantation of PBSCs can produce tro-following permanent focal ischemia or transient global ischemia in the rat cerebral cortex, and shown to persist phic factors including SDF-1, which may compensate for the decline of SDF-1 after stroke and thereby recruit for at least 7 days (22) . Following cerebral ischemia, several HIF-1 target genes are induced in the brain, in-the stem cells for vasculogenesis and neurogenesis (108) . These data imply that SDF-1 may have potential cluding genes that participate in vasodilatation (inducible nitric oxide synthase), angiogenesis (vascular endo-as a gene or protein therapy, for the mobilization of either exogenous or endogenous stem cells for the treat-thelial growth factor, VEGF), energy metabolism and ion transport (glucose transporter 1-GLUT1), and erythropoi-ment of chronic stroke and other chronic neurodegenerative diseases. etin (EPO) (13,103). SDF-1 is the only chemokine family member known to be regulated by HIF-1. Interestingly, GENETIC REGULATION both SDF-1 and hypoxia are present in bone marrow, sug-OF STEM CELL TRAFFICKING gesting that hypoxia may be a fundamental requirement for progenitor cell trafficking and function. As such, is-Although the importance of SDF-1 in stem cell recruitment to injured tissue is well established, the mech-chemic tissue may recruit circulating progenitors regulated by hypoxia through differential expression of HIF-anism underlying the localized expression of SDF-1 in ischemic tissue is still unknown. It has been suggested 1α and SDF-1 (18) (Fig. 1) . Because HIF-1α is stabilized in a variety of different injury states (starvation, hypoxia), that hypoxia rather than specific proinflammatory mediators (such as IL-1β and tumor necrosis factor) regulate it seems plausible that HIF-1-regulated SDF-1 expression may be important in a number of regenerative pathways. SDF-1 expression in vitro (44) . Recent data have shown that SDF-1 expression and EPC recruitment are directly Thus, manipulation of HIF-1 activity may be a useful means with which to augment the body's innate repara-proportional to reduced tissue oxygen tension in vivo (19) . Furthermore, SDF-1 gene expression is regulated tive capacity after ischemic injury (18, 19) . by the transcription factor hypoxic-inducible factor-1 FUTURE PROSPECTS (HIF-1) in endothelial cells, resulting in selective in vivo expression of SDF-1 in ischemic tissue. There is also in There is no doubt that regenerative therapy will serve as a future restorative therapy for stroke. But before vitro evidence that SDF-1 expression is transcriptionally Figure 1 . Schematic representation of the proposed mechanism by which stem cells contribute to the recovery of stroke-injured brain. (A) As a result of ischemic injury, the surviving or invading glia, microglia, and endothelial cells may produce chemoattractants (e.g., SDF-1). Stem cells of exogenous or endogenous origin, by virtue of their expression of chemokine receptors (e.g., CXCR4), are directed toward the ischemic core and penumbra (shaded area). The interaction of stem cells with ischemic tissue may lead stem cells and/or parenchymal cells to produce trophic factors that may contribute to the recovery of tissue injury. These trophic factors also recruit angioblasts, leading to angiogenesis. (B) Endothelial expression of SDF-1, which is in direct proportion to reduced oxygen tension, increases the adhesion, migration, homing to, and subsequent vasculogenesis of circulating CXCR4positive stem cells in ischemic tissue, leading to increased tissue perfusion of damaged tissue. (C) Endothelial SDF-1 gene expression is regulated by the transcription factor hypoxia-inducible factor -1 (HIF-1). Under hypoxic conditions, the rate of HIF-1α degradation is decreased, allowing transcriptional activation of HIF-1 target genes, including vascular endothelial growth factor (VEGF), erythropoietin (EPO), and SDF-1. (D) Following vasculogenesis, new neurons are born and express neuronal lineage markers. These newborn neurons contribute to restored tissue growth in the margin of the lesion cavity, which results in a reduced lesion cavity.
clinical trials with stem cell-based approaches are initi-zyme replacement genes or chemicals, to treat several CNS diseases (84, 111) . ated, we need to know much more about how to control stem cell proliferation and differentiation into specific For maximal functional recovery, regenerative therapy may need combinational approaches, which include cell phenotypes, induce their integration into existing neural and synaptic circuits, and optimize functional re-cell replacement, trophic support, protection from oxidative stress, and the neutralization of growth-inhibitory covery from stroke in animal models (107) . Furthermore, stem cells show tropism toward brain pathology, components against endogenous NSCs (71,88). We also need to identify, with the aid of genomic and proteomic which appears to be mediated at least in part by chemokines. This means that stem cells could be exploited as approaches, the cellular and molecular players that, in concert, can regulate graft-aided CNS plasticity. On the delivery vehicles for therapeutic molecules, such as en- 
